ATC Group: N06DX Other anti-dementia drugs

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N06DX in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N06 Psychoanaleptics
3 N06D Anti-dementia drugs
4 N06DX Other anti-dementia drugs

Group N06DX contents

Code Title
N06DX01 Memantine
N06DX02 Ginkgo folium
N06DX03
N06DX04
N06DX05

Active ingredients in N06DX

Active Ingredient Description
Ginkgo biloba

The exact mechanism of action of ginkgo biloba is not known. Human pharmacological data show increased EEG vigilance in geriatric subjects, reduction in blood viscosity and improved cerebral perfusion in specific areas in healthy men (60-70 years) and reduction in platelet aggregation. Additionally, vasodilating effects on forearm blood vessels causing increased regional blood flow are shown.

Lecanemab

Lecanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer’s disease. Lecanemab reduces amyloid beta plaques, as evaluated in studies.

Memantine

Memantine is a voltage-dependent, moderate-affinity uncompetitive NMDA-receptor antagonist. It modulates the effects of pathologically elevated tonic levels of glutamate that may lead to neuronal dysfunction.

Related product monographs

Title Information Source Document Type  
AXURA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
EBIXA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
EBIXA Oral solution European Medicines Agency (EU) MPI, EU: SmPC
LEQEMBI Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
NEMDATINE Film-coated tablets European Medicines Agency (EU) MPI, EU: SmPC